US20020082517A1 - Tissue marking using biocompatible microparticles - Google Patents
Tissue marking using biocompatible microparticles Download PDFInfo
- Publication number
- US20020082517A1 US20020082517A1 US10/056,882 US5688202A US2002082517A1 US 20020082517 A1 US20020082517 A1 US 20020082517A1 US 5688202 A US5688202 A US 5688202A US 2002082517 A1 US2002082517 A1 US 2002082517A1
- Authority
- US
- United States
- Prior art keywords
- microparticles
- tissue
- site
- biopsy
- marking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer
Definitions
- Tissue marking generally is a method of marking a position in a body, such as a specific position on tissue or an organ, to allow re-visiting of the position at a later time to check for progress or developments of an ailment or a treatment, or to allow re-treatment at the same site.
- tissue marking can be used during biopsy or other tissue-removal procedures to accurately mark the site of the tissue-removal or biopsy, to allow a treatment-giver to later return to the same site if desired, e.g., to monitor the status of the tissue in question, or to do another biopsy.
- tissue marking can be useful in procedures relating to colon or rectum biopsies or tissue removal, prostrate biopsies, or breast biopsies.
- the marker e.g., a radiopaque material
- the marker can be used to help locate the biopsy site in case malignancy is determined, thereby enabling return to the same site and optionally a subsequent treatment such as surgical excision, even if the mammographic findings associated with the original lesions were removed completely.
- One localization method involves placing a metallic clip (e.g., sold under the trade name MicromarkTM, from Biopsys Medical) through an 11-or14-gauge probe of a motorized, vacuum core-cutting biopsy device, and attaching the clip to the site of a biopsy, to mark the location of the biopsy.
- a metallic clip e.g., sold under the trade name MicromarkTM, from Biopsys Medical
- Such clips measure approximately 3 mm across, and are permanent and radiopaque.
- marking clips has been described in the following articles: Burbank, Fred, MD, Farcier, Nancy, MD, “Tissue Marking Clip for Stereotactic Breast Biopsy: Initial Placement Accuracy, Long-term Stability, and Usefulness as a Guide for Wire Localization,” Radiology 1997; 205:407-415; Liberman, Laura, MD, Dershaw, David, MD, Morris, Elizabeth A., MD, Abramson, Andrea F., MD, Thorton, Cynthia M., RT (R)(M), Rosen Paul Peter, MD, “Clip Placement After Stereotactic Vacuum-Assisted Breast Biopsy,” Radiology, 1997; 205:417-422.
- tissue marking is in prostate biopsies. It is recognized that initial biopsies may not be fully determinative in the prostate. See, e.g., Jonathan I., MD, “Are You Getting Maximum Diagnostic and Prognostic Information from your Prostate Needle Biopsy?” Contemporary Urology, 106, April 1999. Tissue marking can ensure that the tissue of non-determinative initial biopsies can be monitored for progressive disease, and that if necessary a follow-up biopsy can be performed at the site of the initial biopsy.
- the invention provides a method of tissue marking.
- the method includes the use of detectable, preferably radiopaque particles delivered to a tissue site for later detection.
- the particles can preferably be delivered into the body to a desired site by injection using a hypodermic needle and syringe, or another similar instrument, or percutaneously, with the assistance of a biopsy probe.
- Microparticles can preferably be of an average size in the range from about 100 to 1000 microns, more preferably from about 200 to 500 microns, and most preferably from about 251 to about 300 microns, in transverse, cross-sectional dimension.
- the microparticles can preferably be permanently radiopaque, and may optionally comprise a carbon coating.
- An optional carbon surface may include, for example, pyrolytic carbon, e.g., isotropic carbon such as low temperature isotropic carbon, vitreous carbon, or any other useful form of carbon.
- the carbon can be coated onto a particle substrate as a thin coating or film, thereby creating a particle having a highly biocompatible carbon surface. While not required, pyrolytic carbon can be preferred.
- the particle substrate can be but is not necessarily biocompatible, and should be capable of withstanding the conditions of the process for coating a carbon surface onto the substrate, which might include elevated temperatures.
- particle substrates can be radiopaque, most preferably permanently radiopaque.
- Exemplary radiopaque materials can include metals and metal oxides such as zirconium oxide and aluminum oxide, gold, titanium, silver, stainless steel, oxides and alloys thereof, etc.
- the microparticles can be delivered using a fluid carrier, which can be any biologically compatible material capable of delivering the microparticles to a desired tissue site, such as a biologically compatible suspension, solution, or other form of a fluid or gel.
- a biologically compatible carrier examples include saline, dextrans, glycerol, polyethylene glycol, corn oil or safflower, other polysaccharides or biocompatible polymers, methyl cellulose, glucan, agarose, etc., either singly or in combination.
- microparticles in tissue marking methods, preferably by injecting through a hypodermic needle and syringe or a like instrument, has advantages over other tissue marking methods. For instance, delivery of microparticles using a needle and syringe allows very precise delivery of microparticle markers to a desired tissue site; this is particularly true if a biopsy probe used to perform a biopsy is used to assist delivery of microparticles for tissue marking, without first moving the biopsy sheath. Additionally, microparticles can be used in tissue locations where other types of tissue markers are not or cannot be used. For example, some tissue locations such as the colon or rectum do not lend themselves to the use of marking clips, yet it is possible to deliver microparticles to these locations for effective marking.
- embodiments of useful microparticles having a carbon-coated surface are very biocompatible.
- preferred embodiments of the microparticles can be permanently radiopaque, e.g., by virtue of a permanently radiopaque particle substrate. The location of permanently radiopaque particles can be monitored, by known methods, for as long as the radiopaque microparticles remain in a body.
- An aspect of the invention relates to a method for tissue marking.
- the method includes delivering detectable microparticles to a tissue site and detecting the microparticles.
- Another aspect of the invention relates to a method of tissue marking.
- the method includes injecting detectable microparticles to a tissue site through a hypodermic needle, and detecting the microparticles.
- Yet another aspect of the invention relates to a method for marking a biopsy.
- the method includes performing a biopsy and marking the site of the biopsy using detectable microparticles injected through a hypodermic needle.
- Yet another aspect of the invention relates to a method for marking a site of tissue removal.
- the method includes performing a tissue removal procedure and marking the site of the tissue removal using detectable microparticles injected through a hypodermic needle.
- biocompatible refers to materials which, in the amount employed, are non-toxic and substantially non-immunogenic when used internally in a patient, and which are substantially insoluble in blood.
- Suitable biocompatible materials include ceramics, metals and metal oxides such as titanium, gold, silver, stainless steel, oxides thereof, aluminum oxide, zirconium oxide, etc., carbon such as pyrolytic carbon or low temperature or ultra low temperature isotropic carbon.
- the term “detectable” refers to materials capable of being detected during or after injection into a mammalian subject, by methods generally used for monitoring and detecting such materials, e.g. magnetic resonance, X-ray, ultrasound, magnetotomography, electrical impedance imaging, light imaging (e.g. confocal microscopy and fluorescence imaging) and nuclear imaging (e.g. scintigraphy, SPECT and PET).
- contrast-enhancing agents such as radiopaque materials. Contrast-enhancing agents may be either water soluble or water insoluble.
- water soluble radiopaque materials include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine.
- water insoluble radiopaque materials include metals and metal oxides such as gold, titanium, silver, stainless steel, oxides thereof, aluminum oxide, zirconium oxide, etc.
- the invention provides methods of marking tissue for any reason, such as to mark the site of the removal of a tissue, e.g., the removal of a polyp from a colon or rectum; to mark the site of a biopsy, including a breast biopsy, a prostate biopsy, a colon biopsy, a rectum biopsy; or to mark the site of any other medical procedure or removal of tissue or biopsy at another tissue location.
- the tissue may be marked for any reason, for example to return to the same tissue site to monitor the progress of a medical condition or a treatment, or to perform a subsequent biopsy at the same site.
- the tissue may be marked to provide a target for radiation treatment, i.e., detectable microparticles can be delivered to a tissue site to act as a target at which or near a beam of radiation can be precisely directed.
- the invention involves marking a tissue site using detectable microparticles, preferably that are also biocompatible.
- the microparticles contain some detectable component (some well-known detectable components are referred to as a “contrast-enhancing agent”) that causes the microparticles to be detectable, e.g., allows the microparticles to be tracked, monitored, or otherwise detected by known methods, including radiography or fluoroscopy.
- the detectable component e.g., contrast-enhancing agent
- Contrast-enhancing agents are well known in the medical arts, with any of a variety of such contrast-enhancing agents being suitable for use according to the methods of the invention
- a detectable component is preferably capable of being substantially immobilized within a microparticle, and may be incorporated into a microparticle for use in tissue marking in any of a variety of ways, e.g., as part of a particle substrate, as a surface coating or an additive to a surface coating such as a carbon coating, or elsewhere.
- a detectable component can be added to a material that is not detectable, e.g., not radiopaque.
- the detectable component may be provided in any location or portion of a microparticle, by known methods. Preferred detectable materials, and their compositions with respect to microparticles, are described below.
- the microparticles comprise a permanently radiopaque material which can be permanently detected within a body following delivery to a tissue site.
- Permanent radiopacity is unlike contrast-enhancing agents or radiopaque materials which biodegrade or otherwise lose their effectiveness (detectability, e.g., radiopacity) over a period of time, e.g., days or weeks, such as 7 to 14 days. (See, e.g., PCT/GB98/02621).
- An advantage of permanent radiopaque materials is that they can be detected for as long as they remain in a body, whereas non-permanent radiopaque materials or other types of contrast-enhancing agents are detectable for only a limited time. See generally, Assignee's copending U.S. patent application Ser. No. 09/602,323, entitled Embolization Using Carbon Coated Microparticles, and filed on Jun. 23, 2000, the full disclosure of which is incorporated herein by reference.
- radiopaque materials include paramagnetic materials (e.g. persistent free radicals) and compounds, salts, and complexes of paramagnetic metal species (for example transition metal or lanthanide ions); heavy atom (i.e. atomic number of 37 or more) compounds, salts, or complexes (e.g. heavy metal compounds, iodinated compounds, etc.); radionuclide-containing compounds, salts, or complexes (e.g. salts, compounds or complexes of radioactive metal isotopes or radiodinated organic compounds); and superparamagentic materials (e.g. metal oxide or mixed oxide particles, particularly iron oxides).
- paramagnetic materials e.g. persistent free radicals
- compounds, salts, and complexes of paramagnetic metal species for example transition metal or lanthanide ions
- heavy atom i.e. atomic number of 37 or more
- radionuclide-containing compounds, salts, or complexes e.g. salts, compounds or
- Preferred paramagnetic metals include Gd (III), Dy (III), Fe (II), Fe (III), Mn (III) and Ho (III), and paramagnetic Ni, Co and Eu species.
- Preferred heavy metals include Pb, Ba, Ag, Au, W, Cu, Bi and lanthanides such as Gd, etc.
- microparticles used for tissue marking should be sufficient to allow detection of the microparticle as desired.
- the amount used in any particular application or microparticle may depend on various factors such as the size of the microparticles, the total amount of microparticles delivered, the type of contrast-enhancing agent, etc.
- microparticles can be made up of 100 percent radiopaque material.
- the microparticles can have any relative amounts of radiopaque particle substrate to carbon coating that will allow the microparticles to be used as detectable tissue markers, for example from about 50 to 100 percent by weight radiopaque particle substrate based on the total weight of the particle substrate and the carbon coating.
- some, i.e., only a portion, but not all microparticles used in a particular tissue marking procedure can include a detectable component.
- the microparticles are completely made up of permanently radiopaque material, preferably in a form that is biologically compatible, and are delivered directly to a tissue site as such.
- microparticles for tissue marking according to the invention can have a surface that comprises carbon.
- the carbon-containing particle surface may be in the form of a carbon-containing coating or carbon-containing film of any type of carbon, e.g., pyrolytic carbon (such as low temperature isotropic or LTI carbon), another type of isotropic carbon, or vitreous carbon, preferably in a form that is biocompatible.
- pyrolytic carbon such as low temperature isotropic or LTI carbon
- LTI carbon low temperature isotropic carbon
- vitreous carbon preferably in a form that is biocompatible.
- Examples of carbon coated particles are described, e.g., in U.S. Pat. No. 5,792,478, the full disclosure of which is incorporated herein by reference.
- pyrolytic carbon e.g., LTI carbon
- vitreous carbon is similar to graphite, a common form of carbon, but the alignment between hexagonal planes of atoms is not as well ordered as in graphite.
- Pyrolytic carbon is characterized by a more chaotic atomic structure with warped hexagonal planes, missing atoms, and generally a more turbostatic appearance. This results in better bonding between layer planes. See Beavan.
- the carbon-coated microparticles can preferably be constructed as a particle substrate having a carbon surface, e.g., a particle substrate having a layer of carbon coated thereon. While the substrate need not be biocompatible due to its being coated with a preferably biocompatible layer comprising carbon, it can be preferred that the particle substrate also be biocompatible.
- Such carbon-coated microparticles may be prepared using any of a variety of coating processes to deposit carbon onto a particle substrate.
- a particle substrate can be selected for compatibility with the coating process, meaning that it should be capable of withstanding temperatures used in a given process for coating carbon onto a particle substrate.
- Relatively hard metallic or ceramic materials capable of withstanding high temperature conditions of a coating process can generally be preferred materials for a particle substrate.
- Metals, metal oxides, and alloys including but not limited to medical grade stainless steel, silver, gold, titanium and titanium alloys, and oxide derivatives of stainless steel or titanium or titanium alloys, are also acceptable materials for the particle substrate, with aluminum oxide, and zirconium oxide being especially suitable.
- the microparticles may include a carbon coating deposited on a carbon particle substrate, and may be substantially or entirely made of carbon.
- both the particle substrate and the carbon coating may comprise pyrolytic carbon.
- Particle substrates intended to be coated with carbon should be of sufficient diameter, shape, and uniformity that they can be coated with carbon, as described, to produce carbon-coated particles of a size, quality, and nature as described herein.
- the particle substrates, prior to coating can be selected and processed, e.g., milled, extruded, sifted, cleaned, filtered, or otherwise formed, etc., to provide a desired combination of particle size, shape, and quality, to result in coated particles of a desired size, shape, and quality.
- Pyrolytic carbon can be produced and coated onto a substrate surface by known methods, e.g., as described in the Beavan article, and in U.S. Pat. No. 5,792,478, cited above.
- hydrocarbons and alloying gases are decomposed to prepare a pyrolytic carbon coating on a particle substrate.
- the particle substrates are included with the hydrocarbons and alloying gases in a fluidized or floating bed at a temperature sufficient to cause deposition of pyrolyzed carbon onto the substrate surface, e.g., from about 1200 to 1500C (see Beavan, p.2).
- Inert gas flow is used to float the bed of particle substrates, optionally including an inert mixing media.
- the hydrocarbon pyrolysis results in a high carbon, low hydrogen content carbon material being deposited as a solid material onto the particle substrates.
- a carbon coating (sometimes referred to as “ultra-low-temperature isotropic carbon”) may be applied to a particle substrate using any one of other various coating processes for depositing carbon, e.g., a vacuum vapor deposition process.
- a vacuum vapor deposition process uses ion beams generated from any of a variety of known processes, such as the disassociation of CO 2 , reactive dissociation in vacuum of a hydrocarbon as a result of a glow discharge, sublimation of a solid graphite source, or cathode sputtering of a graphite source.
- Gold has been found to be an especially suitable substrate material for vacuum vapor deposited carbon.
- Other substrates including but not limited to nickel, silver, stainless steel, or titanium are also quite acceptable as a substrate material for this type of coating process.
- the high strength, resistance to breakdown or corrosion, and durability of a carbon surface ensures effective, long term functioning of microparticles in tissue marking applications.
- the established biocompatibility of carbons such as pyrolytic and vitreous carbon makes the described particles particularly suitable for tissue marking applications.
- the microparticle substrates may be completely encased by a carbon surface. This results in a smooth coated particle with no substrate exposure on the surface of the particle.
- Preferred carbon coatings can be in the range of fractions of thousandths of an inch, e.g., about one half of a thousands of an inch (0.0005 inches), on average, covering the surface of the particle substrate.
- the microparticles are preferably generally rounded particles that have a smooth surface.
- the smooth surface enhances passage of the microparticles through a hypodermic needle.
- Microparticles are preferably subjected to a cleaning and sieving process to remove contaminants and to separate out particles of a size less than or greater than a desired size range.
- the particles may preferably range in size from 100 microns to 1,000 microns in average, transverse cross-sectional dimension, preferably in the range from about 200 to 500 microns, and a particularly preferred size range for use in tissue marking applications can be between about 251 and about 300 microns.
- microparticles may be processed, e.g., segregated to a selected size range, for example using a sieving process such that the minimum microparticle dimension will pass through a U.S. No. 50 Screen Mesh (300 micron grid size opening) but will not pass through a U.S. No. 60 Screen Mesh (250 micron grid size). That minimum dimension will be the transverse, cross-sectional dimension on oblong or elongated particles, with that dimension coinciding with the particle diameter on generally spherical particles.
- Microparticles can be delivered to a tissue site using any instrument or apparatus that can be used to inject an amount of microparticles, preferably contained or suspended in a carrier, through the skin, mucosa, or through an incision in the skin, to a desired tissue site.
- Preferred instruments include instruments such as hypodermic needles or other similar needle-like apparatuses, such as any small bore instrument, cannula, etc.
- tissue marking composition (described below) (i.e., the apparatus components will not readily degrade in the tissue marking composition, and vice versa).
- microparticles can be delivered using a hypodermic needle and a syringe, by inserting the hypodermic needle into a desired tissue site, followed by delivery of the microparticles to the tissue site.
- any of a variety of surgical or non-invasive or minimally-invasive surgical instruments can also be used to assist in delivery.
- a hypodermic needle can be inserted through the mucosa, at the site of the polyp, to deliver microparticles.
- a mammotone inserted through a small incision in the skin can be maintained in the operative position, and a needle can be inserted through its sheath, to precisely deliver microparticles to the site of biopsy.
- microparticles can be slowly injected through the needle to the desired tissue site.
- the microparticles are of a size that can be effectively deposited through a hypodermic needle or like instrument, and that will substantially remain at the tissue site where delivered. If the particles are too small, they can be engulfed by the body's white cells (phagocytes) and carried to distant organs or be carried away in the microvasculature and travel until they reach a site of sufficient constriction to prevent further movement. On the other hand, particles should not be so large that they cannot be effectively delivered using a hypodermic needle or the like.
- a particularly preferred, average microparticle size can be from about 100 to 1000 microns, e.g., 200 to 500 microns, preferably from about 251 to 300 microns, because sizes can allow injection through small bore instruments and are large enough to avoid migration of the microparticles from the injection site. See generally, Malizia, Anthony A., Jr., Reiman, Herbert M., Meyers, Robert P., Sande, Jonathan R., Barham, Steven S., Benson, Ralph C., Jr., Dewanjee, Mrinal K., and Utz, William J., “Migration and Granulomatous Reaction After Periurethral Injection of Polytef (Teflon),” JAMA, Jun. 22/29, 1984 volume 251, No. 24.
- microparticles in tissue marking methods preferably injected by use of a needle and syringe or a like instrument
- delivery of microparticles using a needle and syringe allows very precise delivery of microparticles to a desired tissue site. This is particularly true if the biopsy probe used to perform a biopsy is immediately subsequently used to delivery the microparticles, without first moving the probe sheath.
- Other advantages are that microparticles can be used where other types of tissue markers either cannot be used, or are not used.
- tissue-marking clips are not used in the colon or rectum, whereas microparticles can be injected to these tissues.
- tissue marking clips can sometimes be inadvertently attached to tissue that will move and cause movement of the clip, such as a ligament. The injection of microparticles avoids such problems.
- the amount of microparticles introduced in a tissue marking procedure can be any amount sufficient to mark a location to be detected at a later time.
- the amount delivered can vary depending on factors such as the size of the microparticles the amount of detectable component in the microparticles factors relating to the patient, etc. Such factors will be within the skill of an artisan of ordinary skill in the medical or tissue marking arts, and such an artisan will be able to understand what is a useful amount of microparticles for delivery to body tissue sites.
- the microparticles can be contained and used for delivery in a tissue marking composition comprising an injectable combination of microparticles in a biocompatible carrier.
- the carrier can be any biocompatible fluid capable of delivering the microparticles to a desired tissue site.
- a carrier may include, for example, a biologically compatible suspension, solution, or other form of a fluid or gel. Examples of materials useful in biologically compatible carriers include saline, dextrans, glycerol, polyethylene glycol, corn oil or safflower oil, other polysaccharides or biocompatible polymers, methyl cellulose, glucan, agarose, etc., either singly or in combination.
- the carrier can preferably be an aqueous suspension or solution, other fluid, or gel of polymeric chains of B-D glucose, commonly referred to as ⁇ -glucan.
- the glucose units are linked to each other at the 1-3, 1-4, or 1-6 positions and form polymeric chains ranging to several thousand daltons in weight.
- ⁇ -glucan is a naturally occurring constituent of cell walls in essentially all living systems including plants, yeast, bacteria, and mammalian systems. Its effects and modulating actions on living systems have been studied extensively (see Abel, G., and Czop, J.K., “Stimulation of Human Monocyte B-glucan Receptors by Glucan Particles Induces Production of TNF- ⁇ and 1L-B,” Int. J. Immunopharmacol., 14(8):1363-1373, 1992 and references included therein).
- ⁇ -glucan when administered in experimental studies, elicits and augments host defense mechanisms including the steps required to promote healing by first intent, thereby stimulating the reparative processes in the host system.
- ⁇ -glucan is removed from tissue sites through macrophagic phagocytosis or by enzymatic destruction by serous enzymes.
- Aqueous solutions, suspension, fluids, or gels of ⁇ -glucan can be produced that have favorable physical characteristics as a carrier for microparticles in tissue marking applications.
- the viscosity can vary from a thin liquid to a firm, self-supporting gel. Irrespective of viscosity, the ⁇ -glucan has excellent lubricity, thereby creating a particle-carrier composition which is easily administered by delivery to a predetermined body site through a small bore needle.
- a preferred ⁇ -glucan composition is ⁇ -D-glucan containing 4-0-linked- ⁇ -D-glycopyranosyl units and 3-0-linked- ⁇ -D-glycopyranosyl units.
- the carrier can be of sufficient viscosity to assure that the microparticles remain suspended therein, for a sufficient time duration to accomplish the injection procedure.
- a preferred carrier material is methyl cellulose or another linear unbranched polysaccharide.
- suitable carrier materials include agarose, hyaluronic acid, polyvinyl pyrrolidone or a hydrogel derivative thereof, dextran or a hydrogel derivative thereof, glycerol, polyethylene glycol, succinylated collagen, liquid collagen, oil-based emulsions such as corn or safflower, or other polysaccharides or biocompatible organic polymers either singly or in combination with one or more of the above-referenced solutions.
- the amount of microparticles to carrier in a tissue marking composition can be any amount that will provide a tissue marking composition that is flowable and injectable, and that will allow a desired amount of microparticles to be delivered to a tissue site.
- Preferred amounts of microparticles in a tissue marking composition can be in the range from about 20 to 60 percent by volume, more preferably from about 25 to 40 percent by volume.
- the tissue marking composition can typically be injected in a fluid state, e.g., as a slurry, suspension, or emulsion, through a needle, into a body tissue site.
- a fluid state e.g., as a slurry, suspension, or emulsion
- the carrier When deposited into a body tissue, the carrier will be carried away into the body, e.g., through the blood stream, and disperse or be destroyed. It is necessary that at least some of the microparticles, preferably most or substantially all of the microparticles, are substantially immobile upon deliver to a tissue site for marking.
- Microparticles used for tissue marking according to the invention are sufficiently immobile to be used for tissue marking applications; if the microparticles tend to move at all after delivery to a tissue site, the microparticles generally will do so only up the path of the needle used to inject them.
- tissue marking applications are considered to be within the contemplation of the present invention.
- tissue marking applications include other types of biopsy applications such as colon, rectum, or prostate biopsies, and non-biopsy applications including tissue marking for other types of medical procedures such as tissue removal, e.g., the removal of polyps from the rectum or colon.
- the tissue may be marked to provide a target for radiation treatment, i.e., detectable microparticles can be delivered to a tissue site to act as a target at which a beam of radiation can be precisely directed.
- detectable microparticles can be used in these and other tissue marking or biopsy processes e.g., by guiding a delivery apparatus to a desired body tissue and delivering an amount of the microparticles to the site, for detection at that site at a later time.
- Factors that might be considered, controlled, or adjusted for in applying the process to a particular tissue marking application might include consideration of the composition of the microparticles; the amount of microparticles to be delivered to the body site; factors relating to the method of delivery including the particular equipment (e.g., needle or biopsy probe) used for delivery, and the method and route used to place the dispensing end of the delivery device at the desired body site; etc. All of these factors will be appreciated by one of ordinary skill in the tissue marking or medical arts, and can be readily dealt with to apply the described methods to a wide variety of tissue marking procedures.
- the particular equipment e.g., needle or biopsy probe
- Biopsy is a method by which a tissue sample is removed from a site of a body to diagnose the tissue as healthy or diseased, e.g., carcinogenic. Biopsies are performed on tissues of many different body organs, including prostate and breast tissues. The means used to perform the biopsy can include any equipment and techniques generally known or useful in biopsy procedures.
- Breast biopsies can be performed using stereotactic, vacuum-assisted breast biopsy techniques and equipment therefore. Such techniques and equipment involve the use of minimally invasive instruments and techniques such as automated surgical biopsy devices. These methods and devices relate to percutaneous procedures that include inserting a needle-like instrument through a very small incision in the breast to access the tissue mass of interest and obtain a tissue sample for later examination and analysis. See, e.g., U.S. Pat. No. 6,086,544, incorporated herein by reference.
- BIOPSYS mammotone breast biopsy system sold under the trade name BIOPSYS, from Ethicon Endo-Surgery, Inc.
- detectable microparticles can be used to mark the site of a biopsy, e.g., a breast biopsy.
- the microparticles can be used to locate the biopsy site in case malignancy is determined, thereby enabling a return to the site and subsequent surgical treatment, e.g., excision, even if the mammographic findings associated with the original lesions were removed completely.
- the detectable microparticles can be delivered to the site of the breast biopsy using any sort of a needle delivery system.
- microparticles can be delivered using the same biopsy equipment, e.g., the same biopsy sheath, as used to perform the biopsy, so as to achieve very precise marking of the biopsied site.
- the objective of the research study was to determine the qualitative and quantitive persistence of the radiopaque pyrolytic carbon coated beads.
- Rabbits were selected as the most appropriate species for this study for the following reasons: Auricular injection has frequently been used to quantify the persistence of materials. The cartilage in the ear provides a substrate over which the material can be inserted and subsequently measured. Migration from the insertion site proximally can be readily observed. Rabbits also provide a “non-growing” model. Therefore the effects of growth are not a study factor. The relative constancy of the landmarks in a smaller animal allows bony landmarks for dissection at necropsy.
- the ears were examined for migration of beads from the site of injection. The examinations were accomplished by tran-illuminating the tissues with bright light. No particles were observed beyond the boundaries of the lesions.
- Radiopaque carbon coated beads were injected subcutaneously between the skin and the auricular cartilage on the convex surface of ears, and subs-serosally along the greater curvature of the stomach in rabbits. Weekly examination demonstrated minimal inflammatory response to the injected area. At 5 weeks (ear) and 8 weeks (stomach/esophagus) post-procedure the radiopaque beads appeared stable in place.
Abstract
Description
- Tissue marking generally is a method of marking a position in a body, such as a specific position on tissue or an organ, to allow re-visiting of the position at a later time to check for progress or developments of an ailment or a treatment, or to allow re-treatment at the same site. As an example, tissue marking can be used during biopsy or other tissue-removal procedures to accurately mark the site of the tissue-removal or biopsy, to allow a treatment-giver to later return to the same site if desired, e.g., to monitor the status of the tissue in question, or to do another biopsy.
- Such tissue marking can be useful in procedures relating to colon or rectum biopsies or tissue removal, prostrate biopsies, or breast biopsies.
- Specifically with respect to breast biopsies, it is not uncommon in modern breast biopsies, e.g., using a mammotone breast biopsy system sold under the trademark name BIOPSYS, from Ethicon Endo-Surgery, Inc., for all evidence of a lesion to be removed during biopsy. Removing all trace of the tissue also removes identifying features from the site, and makes it difficult to return to the same location later, to re-check the site. This dilemma, created by a removal of a potentially malignant breast mass or cluster of microcalcifications during core biopsy, can be ameliorated by placing radiographically visible markers immediately after the biopsy. The marker, e.g., a radiopaque material, can be used to help locate the biopsy site in case malignancy is determined, thereby enabling return to the same site and optionally a subsequent treatment such as surgical excision, even if the mammographic findings associated with the original lesions were removed completely.
- One localization method involves placing a metallic clip (e.g., sold under the trade name Micromark™, from Biopsys Medical) through an 11-or14-gauge probe of a motorized, vacuum core-cutting biopsy device, and attaching the clip to the site of a biopsy, to mark the location of the biopsy. Such clips measure approximately 3 mm across, and are permanent and radiopaque. The use of marking clips has been described in the following articles: Burbank, Fred, MD, Farcier, Nancy, MD, “Tissue Marking Clip for Stereotactic Breast Biopsy: Initial Placement Accuracy, Long-term Stability, and Usefulness as a Guide for Wire Localization,” Radiology 1997; 205:407-415; Liberman, Laura, MD, Dershaw, David, MD, Morris, Elizabeth A., MD, Abramson, Andrea F., MD, Thorton, Cynthia M., RT (R)(M), Rosen Paul Peter, MD, “Clip Placement After Stereotactic Vacuum-Assisted Breast Biopsy,” Radiology, 1997; 205:417-422.
- Another example of an application for tissue marking is in prostate biopsies. It is recognized that initial biopsies may not be fully determinative in the prostate. See, e.g., Jonathan I., MD, “Are You Getting Maximum Diagnostic and Prognostic Information from your Prostate Needle Biopsy?” Contemporary Urology, 106, April 1999. Tissue marking can ensure that the tissue of non-determinative initial biopsies can be monitored for progressive disease, and that if necessary a follow-up biopsy can be performed at the site of the initial biopsy.
- Other methods of tissue marking or “localization” are described in articles of the technical literature: see e.g., Fajardo, Laurie L., MD, Bird, Richard E., MD, Herman, Cheryl R., MD, DeAngalis, Gia A., MD, “Placement of Endovascular Embolization Microcoils to Localize the Site of Breast Lesions Removal at Sterotactic Core Biopsy,” Radiology, 1998, 206: 275-278. Still another method of localizing breast lesions is described at Goldberg, Ronald P., MD, Hall, Ferris M., M.D., and Simon, Morris, MD. “Preoperative Localization of Non-Palpable Breast Lesions Using a Wire Marker and Perforated Mammographic Grid,” Radiology 146: 833-835, March 1983; see also U.S. Pat. Nos. 4,341,220 and 5,665,092.
- The invention provides a method of tissue marking. The method includes the use of detectable, preferably radiopaque particles delivered to a tissue site for later detection. The particles can preferably be delivered into the body to a desired site by injection using a hypodermic needle and syringe, or another similar instrument, or percutaneously, with the assistance of a biopsy probe. Microparticles can preferably be of an average size in the range from about 100 to 1000 microns, more preferably from about 200 to 500 microns, and most preferably from about 251 to about 300 microns, in transverse, cross-sectional dimension. The microparticles can preferably be permanently radiopaque, and may optionally comprise a carbon coating.
- An optional carbon surface may include, for example, pyrolytic carbon, e.g., isotropic carbon such as low temperature isotropic carbon, vitreous carbon, or any other useful form of carbon. The carbon can be coated onto a particle substrate as a thin coating or film, thereby creating a particle having a highly biocompatible carbon surface. While not required, pyrolytic carbon can be preferred.
- The particle substrate can be but is not necessarily biocompatible, and should be capable of withstanding the conditions of the process for coating a carbon surface onto the substrate, which might include elevated temperatures. In particularly preferred embodiments, particle substrates can be radiopaque, most preferably permanently radiopaque. Exemplary radiopaque materials can include metals and metal oxides such as zirconium oxide and aluminum oxide, gold, titanium, silver, stainless steel, oxides and alloys thereof, etc.
- The microparticles can be delivered using a fluid carrier, which can be any biologically compatible material capable of delivering the microparticles to a desired tissue site, such as a biologically compatible suspension, solution, or other form of a fluid or gel. Examples of materials useful in biologically compatible carriers include saline, dextrans, glycerol, polyethylene glycol, corn oil or safflower, other polysaccharides or biocompatible polymers, methyl cellulose, glucan, agarose, etc., either singly or in combination.
- The use of microparticles in tissue marking methods, preferably by injecting through a hypodermic needle and syringe or a like instrument, has advantages over other tissue marking methods. For instance, delivery of microparticles using a needle and syringe allows very precise delivery of microparticle markers to a desired tissue site; this is particularly true if a biopsy probe used to perform a biopsy is used to assist delivery of microparticles for tissue marking, without first moving the biopsy sheath. Additionally, microparticles can be used in tissue locations where other types of tissue markers are not or cannot be used. For example, some tissue locations such as the colon or rectum do not lend themselves to the use of marking clips, yet it is possible to deliver microparticles to these locations for effective marking. And, embodiments of useful microparticles having a carbon-coated surface are very biocompatible. As another advantage, preferred embodiments of the microparticles can be permanently radiopaque, e.g., by virtue of a permanently radiopaque particle substrate. The location of permanently radiopaque particles can be monitored, by known methods, for as long as the radiopaque microparticles remain in a body.
- An aspect of the invention relates to a method for tissue marking. The method includes delivering detectable microparticles to a tissue site and detecting the microparticles.
- Another aspect of the invention relates to a method of tissue marking. The method includes injecting detectable microparticles to a tissue site through a hypodermic needle, and detecting the microparticles.
- Yet another aspect of the invention relates to a method for marking a biopsy. The method includes performing a biopsy and marking the site of the biopsy using detectable microparticles injected through a hypodermic needle.
- Yet another aspect of the invention relates to a method for marking a site of tissue removal. The method includes performing a tissue removal procedure and marking the site of the tissue removal using detectable microparticles injected through a hypodermic needle.
- For purposes of the present disclosure, the following terms shall be given the following meanings.
- The term “biocompatible,” refers to materials which, in the amount employed, are non-toxic and substantially non-immunogenic when used internally in a patient, and which are substantially insoluble in blood. Suitable biocompatible materials include ceramics, metals and metal oxides such as titanium, gold, silver, stainless steel, oxides thereof, aluminum oxide, zirconium oxide, etc., carbon such as pyrolytic carbon or low temperature or ultra low temperature isotropic carbon.
- The term “detectable” refers to materials capable of being detected during or after injection into a mammalian subject, by methods generally used for monitoring and detecting such materials, e.g. magnetic resonance, X-ray, ultrasound, magnetotomography, electrical impedance imaging, light imaging (e.g. confocal microscopy and fluorescence imaging) and nuclear imaging (e.g. scintigraphy, SPECT and PET). Examples include contrast-enhancing agents such as radiopaque materials. Contrast-enhancing agents may be either water soluble or water insoluble. Examples of water soluble radiopaque materials include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine. Examples of water insoluble radiopaque materials include metals and metal oxides such as gold, titanium, silver, stainless steel, oxides thereof, aluminum oxide, zirconium oxide, etc.
- The invention provides methods of marking tissue for any reason, such as to mark the site of the removal of a tissue, e.g., the removal of a polyp from a colon or rectum; to mark the site of a biopsy, including a breast biopsy, a prostate biopsy, a colon biopsy, a rectum biopsy; or to mark the site of any other medical procedure or removal of tissue or biopsy at another tissue location. The tissue may be marked for any reason, for example to return to the same tissue site to monitor the progress of a medical condition or a treatment, or to perform a subsequent biopsy at the same site. Or, the tissue may be marked to provide a target for radiation treatment, i.e., detectable microparticles can be delivered to a tissue site to act as a target at which or near a beam of radiation can be precisely directed.
- The invention, generally stated, involves marking a tissue site using detectable microparticles, preferably that are also biocompatible. The microparticles contain some detectable component (some well-known detectable components are referred to as a “contrast-enhancing agent”) that causes the microparticles to be detectable, e.g., allows the microparticles to be tracked, monitored, or otherwise detected by known methods, including radiography or fluoroscopy. The detectable component, e.g., contrast-enhancing agent, can be any material capable of enhancing contrast in a desired imaging modality (e.g. magnetic resonance, X-ray, ultrasound, magnetotomography, electrical impedance imaging, light imaging (e.g. confocal microscopy and fluorescence imaging) and nuclear imaging (e.g. scintigraphy, SPECT and PET)). Contrast-enhancing agents are well known in the medical arts, with any of a variety of such contrast-enhancing agents being suitable for use according to the methods of the invention
- A detectable component is preferably capable of being substantially immobilized within a microparticle, and may be incorporated into a microparticle for use in tissue marking in any of a variety of ways, e.g., as part of a particle substrate, as a surface coating or an additive to a surface coating such as a carbon coating, or elsewhere. In one sense, a detectable component can be added to a material that is not detectable, e.g., not radiopaque. The detectable component may be provided in any location or portion of a microparticle, by known methods. Preferred detectable materials, and their compositions with respect to microparticles, are described below.
- According to a preferred mode of the invention, the microparticles comprise a permanently radiopaque material which can be permanently detected within a body following delivery to a tissue site. Permanent radiopacity is unlike contrast-enhancing agents or radiopaque materials which biodegrade or otherwise lose their effectiveness (detectability, e.g., radiopacity) over a period of time, e.g., days or weeks, such as 7 to 14 days. (See, e.g., PCT/GB98/02621). An advantage of permanent radiopaque materials is that they can be detected for as long as they remain in a body, whereas non-permanent radiopaque materials or other types of contrast-enhancing agents are detectable for only a limited time. See generally, Assignee's copending U.S. patent application Ser. No. 09/602,323, entitled Embolization Using Carbon Coated Microparticles, and filed on Jun. 23, 2000, the full disclosure of which is incorporated herein by reference.
- Some examples of radiopaque materials include paramagnetic materials (e.g. persistent free radicals) and compounds, salts, and complexes of paramagnetic metal species (for example transition metal or lanthanide ions); heavy atom (i.e. atomic number of 37 or more) compounds, salts, or complexes (e.g. heavy metal compounds, iodinated compounds, etc.); radionuclide-containing compounds, salts, or complexes (e.g. salts, compounds or complexes of radioactive metal isotopes or radiodinated organic compounds); and superparamagentic materials (e.g. metal oxide or mixed oxide particles, particularly iron oxides). Preferred paramagnetic metals include Gd (III), Dy (III), Fe (II), Fe (III), Mn (III) and Ho (III), and paramagnetic Ni, Co and Eu species. Preferred heavy metals include Pb, Ba, Ag, Au, W, Cu, Bi and lanthanides such as Gd, etc.
- The amount of detectable material included in a microparticle used for tissue marking should be sufficient to allow detection of the microparticle as desired. The amount used in any particular application or microparticle may depend on various factors such as the size of the microparticles, the total amount of microparticles delivered, the type of contrast-enhancing agent, etc. According to some embodiments of the invention, microparticles can be made up of 100 percent radiopaque material. Alternatively, for radiopaque particles that are coated with a carbon surface, e.g., as described below, the microparticles can have any relative amounts of radiopaque particle substrate to carbon coating that will allow the microparticles to be used as detectable tissue markers, for example from about 50 to 100 percent by weight radiopaque particle substrate based on the total weight of the particle substrate and the carbon coating. Optionally, some, i.e., only a portion, but not all microparticles used in a particular tissue marking procedure (tissue marking composition, as described below) can include a detectable component.
- In one preferred embodiment of the invention, the microparticles are completely made up of permanently radiopaque material, preferably in a form that is biologically compatible, and are delivered directly to a tissue site as such.
- In another embodiment, microparticles for tissue marking according to the invention can have a surface that comprises carbon. The carbon-containing particle surface may be in the form of a carbon-containing coating or carbon-containing film of any type of carbon, e.g., pyrolytic carbon (such as low temperature isotropic or LTI carbon), another type of isotropic carbon, or vitreous carbon, preferably in a form that is biocompatible. Various forms of carbon are described in the article “Material Properties and Applications of Pyrolite® Carbon,” by Al Beavan, as published inMaterials Engineering, February 1990, incorporated herein by reference. Examples of carbon coated particles are described, e.g., in U.S. Pat. No. 5,792,478, the full disclosure of which is incorporated herein by reference.
- The atomic structure of both pyrolytic, e.g., LTI carbon, and vitreous carbon is similar to graphite, a common form of carbon, but the alignment between hexagonal planes of atoms is not as well ordered as in graphite. Pyrolytic carbon is characterized by a more chaotic atomic structure with warped hexagonal planes, missing atoms, and generally a more turbostatic appearance. This results in better bonding between layer planes. See Beavan.
- The carbon-coated microparticles can preferably be constructed as a particle substrate having a carbon surface, e.g., a particle substrate having a layer of carbon coated thereon. While the substrate need not be biocompatible due to its being coated with a preferably biocompatible layer comprising carbon, it can be preferred that the particle substrate also be biocompatible.
- Such carbon-coated microparticles may be prepared using any of a variety of coating processes to deposit carbon onto a particle substrate. A particle substrate can be selected for compatibility with the coating process, meaning that it should be capable of withstanding temperatures used in a given process for coating carbon onto a particle substrate. Relatively hard metallic or ceramic materials capable of withstanding high temperature conditions of a coating process can generally be preferred materials for a particle substrate. Metals, metal oxides, and alloys, including but not limited to medical grade stainless steel, silver, gold, titanium and titanium alloys, and oxide derivatives of stainless steel or titanium or titanium alloys, are also acceptable materials for the particle substrate, with aluminum oxide, and zirconium oxide being especially suitable. Carbon itself in any of its various forms, e.g., pyrolytic carbon, non-pyrolytic carbon, isotropic carbon, graphite, or vitreous carbon, may be useful as a particle substrate material. Thus, the microparticles may include a carbon coating deposited on a carbon particle substrate, and may be substantially or entirely made of carbon. In one embodiment of the invention, both the particle substrate and the carbon coating may comprise pyrolytic carbon.
- Particle substrates intended to be coated with carbon, whatever their composition, should be of sufficient diameter, shape, and uniformity that they can be coated with carbon, as described, to produce carbon-coated particles of a size, quality, and nature as described herein. Preferably, the particle substrates, prior to coating, can be selected and processed, e.g., milled, extruded, sifted, cleaned, filtered, or otherwise formed, etc., to provide a desired combination of particle size, shape, and quality, to result in coated particles of a desired size, shape, and quality.
- Pyrolytic carbon can be produced and coated onto a substrate surface by known methods, e.g., as described in the Beavan article, and in U.S. Pat. No. 5,792,478, cited above. Generally, hydrocarbons and alloying gases are decomposed to prepare a pyrolytic carbon coating on a particle substrate. The particle substrates are included with the hydrocarbons and alloying gases in a fluidized or floating bed at a temperature sufficient to cause deposition of pyrolyzed carbon onto the substrate surface, e.g., from about 1200 to 1500C (see Beavan, p.2). Inert gas flow is used to float the bed of particle substrates, optionally including an inert mixing media. The hydrocarbon pyrolysis results in a high carbon, low hydrogen content carbon material being deposited as a solid material onto the particle substrates.
- Alternatively, a carbon coating (sometimes referred to as “ultra-low-temperature isotropic carbon”) may be applied to a particle substrate using any one of other various coating processes for depositing carbon, e.g., a vacuum vapor deposition process. Such a method uses ion beams generated from any of a variety of known processes, such as the disassociation of CO2, reactive dissociation in vacuum of a hydrocarbon as a result of a glow discharge, sublimation of a solid graphite source, or cathode sputtering of a graphite source. Gold has been found to be an especially suitable substrate material for vacuum vapor deposited carbon. Other substrates, including but not limited to nickel, silver, stainless steel, or titanium are also quite acceptable as a substrate material for this type of coating process.
- The high strength, resistance to breakdown or corrosion, and durability of a carbon surface ensures effective, long term functioning of microparticles in tissue marking applications. The established biocompatibility of carbons such as pyrolytic and vitreous carbon makes the described particles particularly suitable for tissue marking applications. The microparticle substrates may be completely encased by a carbon surface. This results in a smooth coated particle with no substrate exposure on the surface of the particle. Preferred carbon coatings can be in the range of fractions of thousandths of an inch, e.g., about one half of a thousands of an inch (0.0005 inches), on average, covering the surface of the particle substrate.
- The microparticles, whether coated or uncoated, are preferably generally rounded particles that have a smooth surface. The smooth surface enhances passage of the microparticles through a hypodermic needle. Microparticles are preferably subjected to a cleaning and sieving process to remove contaminants and to separate out particles of a size less than or greater than a desired size range. The particles may preferably range in size from 100 microns to 1,000 microns in average, transverse cross-sectional dimension, preferably in the range from about 200 to 500 microns, and a particularly preferred size range for use in tissue marking applications can be between about 251 and about 300 microns. To achieve this most preferred such size range, microparticles may be processed, e.g., segregated to a selected size range, for example using a sieving process such that the minimum microparticle dimension will pass through a U.S. No. 50 Screen Mesh (300 micron grid size opening) but will not pass through a U.S. No. 60 Screen Mesh (250 micron grid size). That minimum dimension will be the transverse, cross-sectional dimension on oblong or elongated particles, with that dimension coinciding with the particle diameter on generally spherical particles.
- Microparticles can be delivered to a tissue site using any instrument or apparatus that can be used to inject an amount of microparticles, preferably contained or suspended in a carrier, through the skin, mucosa, or through an incision in the skin, to a desired tissue site. Preferred instruments include instruments such as hypodermic needles or other similar needle-like apparatuses, such as any small bore instrument, cannula, etc. (All of these types of instruments will be referred to collectively herein, for convenience, using the term “hypodermic needle” or “needle.”) The particular instrument used for delivery is not critical, provided that its components are compatible with the tissue marking composition (described below) (i.e., the apparatus components will not readily degrade in the tissue marking composition, and vice versa).
- According to one specific example of a method of delivering microparticles for tissue marking, microparticles can be delivered using a hypodermic needle and a syringe, by inserting the hypodermic needle into a desired tissue site, followed by delivery of the microparticles to the tissue site.
- Optionally, any of a variety of surgical or non-invasive or minimally-invasive surgical instruments can also be used to assist in delivery. For example, following removal of a polyp from a colon or a rectum, by known surgical methods, a hypodermic needle can be inserted through the mucosa, at the site of the polyp, to deliver microparticles. As another example, relating to breast biopsies, a mammotone inserted through a small incision in the skin can be maintained in the operative position, and a needle can be inserted through its sheath, to precisely deliver microparticles to the site of biopsy.
- Once a needle is in place (e.g., during or soon after a biopsy or tissue removal has been performed) microparticles can be slowly injected through the needle to the desired tissue site. The microparticles are of a size that can be effectively deposited through a hypodermic needle or like instrument, and that will substantially remain at the tissue site where delivered. If the particles are too small, they can be engulfed by the body's white cells (phagocytes) and carried to distant organs or be carried away in the microvasculature and travel until they reach a site of sufficient constriction to prevent further movement. On the other hand, particles should not be so large that they cannot be effectively delivered using a hypodermic needle or the like. For the method of the present invention, a particularly preferred, average microparticle size can be from about 100 to 1000 microns, e.g., 200 to 500 microns, preferably from about 251 to 300 microns, because sizes can allow injection through small bore instruments and are large enough to avoid migration of the microparticles from the injection site. See generally, Malizia, Anthony A., Jr., Reiman, Herbert M., Meyers, Robert P., Sande, Jonathan R., Barham, Steven S., Benson, Ralph C., Jr., Dewanjee, Mrinal K., and Utz, William J., “Migration and Granulomatous Reaction After Periurethral Injection of Polytef (Teflon),” JAMA, Jun. 22/29, 1984 volume 251, No. 24.
- The use of microparticles in tissue marking methods, preferably injected by use of a needle and syringe or a like instrument, has advantages over the use of other tissue marking methods. For instance, delivery of microparticles using a needle and syringe allows very precise delivery of microparticles to a desired tissue site. This is particularly true if the biopsy probe used to perform a biopsy is immediately subsequently used to delivery the microparticles, without first moving the probe sheath. Other advantages are that microparticles can be used where other types of tissue markers either cannot be used, or are not used. Specifically, tissue-marking clips are not used in the colon or rectum, whereas microparticles can be injected to these tissues. Additionally, tissue marking clips can sometimes be inadvertently attached to tissue that will move and cause movement of the clip, such as a ligament. The injection of microparticles avoids such problems.
- The amount of microparticles introduced in a tissue marking procedure can be any amount sufficient to mark a location to be detected at a later time. The amount delivered can vary depending on factors such as the size of the microparticles the amount of detectable component in the microparticles factors relating to the patient, etc. Such factors will be within the skill of an artisan of ordinary skill in the medical or tissue marking arts, and such an artisan will be able to understand what is a useful amount of microparticles for delivery to body tissue sites.
- According to the invention, the microparticles can be contained and used for delivery in a tissue marking composition comprising an injectable combination of microparticles in a biocompatible carrier. The carrier can be any biocompatible fluid capable of delivering the microparticles to a desired tissue site. A carrier may include, for example, a biologically compatible suspension, solution, or other form of a fluid or gel. Examples of materials useful in biologically compatible carriers include saline, dextrans, glycerol, polyethylene glycol, corn oil or safflower oil, other polysaccharides or biocompatible polymers, methyl cellulose, glucan, agarose, etc., either singly or in combination.
- The carrier can preferably be an aqueous suspension or solution, other fluid, or gel of polymeric chains of B-D glucose, commonly referred to as β-glucan. The glucose units are linked to each other at the 1-3, 1-4, or 1-6 positions and form polymeric chains ranging to several thousand daltons in weight.
- β-glucan is a naturally occurring constituent of cell walls in essentially all living systems including plants, yeast, bacteria, and mammalian systems. Its effects and modulating actions on living systems have been studied extensively (see Abel, G., and Czop, J.K., “Stimulation of Human Monocyte B-glucan Receptors by Glucan Particles Induces Production of TNF-∂ and 1L-B,”Int. J. Immunopharmacol., 14(8):1363-1373, 1992 and references included therein). β-glucan, when administered in experimental studies, elicits and augments host defense mechanisms including the steps required to promote healing by first intent, thereby stimulating the reparative processes in the host system. β-glucan is removed from tissue sites through macrophagic phagocytosis or by enzymatic destruction by serous enzymes. The destruction or removal of β-glucan, as well as its available viscosity and lubricous nature, make it a useful carrier for the microparticles in tissue marking applications.
- Aqueous solutions, suspension, fluids, or gels of β-glucan can be produced that have favorable physical characteristics as a carrier for microparticles in tissue marking applications. The viscosity can vary from a thin liquid to a firm, self-supporting gel. Irrespective of viscosity, the β-glucan has excellent lubricity, thereby creating a particle-carrier composition which is easily administered by delivery to a predetermined body site through a small bore needle. A preferred β-glucan composition is β-D-glucan containing 4-0-linked-β-D-glycopyranosyl units and 3-0-linked-β-D-glycopyranosyl units. The carrier can be of sufficient viscosity to assure that the microparticles remain suspended therein, for a sufficient time duration to accomplish the injection procedure.
- Another example of a preferred carrier material is methyl cellulose or another linear unbranched polysaccharide. Further examples of appropriate carrier materials include agarose, hyaluronic acid, polyvinyl pyrrolidone or a hydrogel derivative thereof, dextran or a hydrogel derivative thereof, glycerol, polyethylene glycol, succinylated collagen, liquid collagen, oil-based emulsions such as corn or safflower, or other polysaccharides or biocompatible organic polymers either singly or in combination with one or more of the above-referenced solutions.
- The amount of microparticles to carrier in a tissue marking composition can be any amount that will provide a tissue marking composition that is flowable and injectable, and that will allow a desired amount of microparticles to be delivered to a tissue site. Preferred amounts of microparticles in a tissue marking composition can be in the range from about 20 to 60 percent by volume, more preferably from about 25 to 40 percent by volume.
- In use, the tissue marking composition can typically be injected in a fluid state, e.g., as a slurry, suspension, or emulsion, through a needle, into a body tissue site. When deposited into a body tissue, the carrier will be carried away into the body, e.g., through the blood stream, and disperse or be destroyed. It is necessary that at least some of the microparticles, preferably most or substantially all of the microparticles, are substantially immobile upon deliver to a tissue site for marking. Microparticles used for tissue marking according to the invention are sufficiently immobile to be used for tissue marking applications; if the microparticles tend to move at all after delivery to a tissue site, the microparticles generally will do so only up the path of the needle used to inject them.
- While subsequent portions of the description include language relating specifically to tissue marking in breast biopsy applications, all types of tissue marking applications are considered to be within the contemplation of the present invention. Examples include other types of biopsy applications such as colon, rectum, or prostate biopsies, and non-biopsy applications including tissue marking for other types of medical procedures such as tissue removal, e.g., the removal of polyps from the rectum or colon. Or, the tissue may be marked to provide a target for radiation treatment, i.e., detectable microparticles can be delivered to a tissue site to act as a target at which a beam of radiation can be precisely directed. One of ordinary skill in the medical or biopsy arts will understand and appreciate how detectable microparticles can be used in these and other tissue marking or biopsy processes e.g., by guiding a delivery apparatus to a desired body tissue and delivering an amount of the microparticles to the site, for detection at that site at a later time.
- Factors that might be considered, controlled, or adjusted for in applying the process to a particular tissue marking application might include consideration of the composition of the microparticles; the amount of microparticles to be delivered to the body site; factors relating to the method of delivery including the particular equipment (e.g., needle or biopsy probe) used for delivery, and the method and route used to place the dispensing end of the delivery device at the desired body site; etc. All of these factors will be appreciated by one of ordinary skill in the tissue marking or medical arts, and can be readily dealt with to apply the described methods to a wide variety of tissue marking procedures.
- Biopsy is a method by which a tissue sample is removed from a site of a body to diagnose the tissue as healthy or diseased, e.g., carcinogenic. Biopsies are performed on tissues of many different body organs, including prostate and breast tissues. The means used to perform the biopsy can include any equipment and techniques generally known or useful in biopsy procedures.
- Breast biopsies can be performed using stereotactic, vacuum-assisted breast biopsy techniques and equipment therefore. Such techniques and equipment involve the use of minimally invasive instruments and techniques such as automated surgical biopsy devices. These methods and devices relate to percutaneous procedures that include inserting a needle-like instrument through a very small incision in the breast to access the tissue mass of interest and obtain a tissue sample for later examination and analysis. See, e.g., U.S. Pat. No. 6,086,544, incorporated herein by reference. It is not uncommon in modern breast biopsies, e.g., using a mammotone breast biopsy system sold under the trade name BIOPSYS, from Ethicon Endo-Surgery, Inc., for all evidence of a lesion to be removed during the biopsy.
- According to the invention, detectable microparticles can be used to mark the site of a biopsy, e.g., a breast biopsy. The microparticles can be used to locate the biopsy site in case malignancy is determined, thereby enabling a return to the site and subsequent surgical treatment, e.g., excision, even if the mammographic findings associated with the original lesions were removed completely.
- The detectable microparticles can be delivered to the site of the breast biopsy using any sort of a needle delivery system. According to a preferred method of the invention, microparticles can be delivered using the same biopsy equipment, e.g., the same biopsy sheath, as used to perform the biopsy, so as to achieve very precise marking of the biopsied site.
- A rabbit research study was conducted to evaluate potential applications of radiopaque pyrolytic carbon coated zirconium oxide beads.
- The following is a summary of the study results:
- Study Objective
- The objective of the research study was to determine the qualitative and quantitive persistence of the radiopaque pyrolytic carbon coated beads.
- Model Description
- Rabbits were selected as the most appropriate species for this study for the following reasons: Auricular injection has frequently been used to quantify the persistence of materials. The cartilage in the ear provides a substrate over which the material can be inserted and subsequently measured. Migration from the insertion site proximally can be readily observed. Rabbits also provide a “non-growing” model. Therefore the effects of growth are not a study factor. The relative constancy of the landmarks in a smaller animal allows bony landmarks for dissection at necropsy.
- The study called for injection of the carbon coated beads into rabbits in the following locations:
- Ear subcutaneous tissue
- Stomach/esophagus sub-mucosa
- Large intestine/colon sub-mucosa
- The rabbit's large intestine lining was found to be too thin for the injection needle and so the efforts in this location were abandoned; only the ear and stomach/esophagus locations were possible.
- A total of 5 rabbits had injections (0.5-1.0 ml) in both ears and 2 rabbits had a total of 7 injections (0.25 ml each) in the intestine/stomach location.
- Measurements
- Persistence in location was measured by radiography and necropsy. Flat film radiographs were taken pre-and post-procedure to document persistence and non-migration. Radiographs were taken at sacrifice to document non-migration (stomach/esophagus).
- Results
- Ear
- Procedure
- Volumes between 0.5-10 ml of beads were injected in both ears of 5 rabbits. The beads were injected subcutaneously between the skin and the auricular cartilage on the convex surface of the ear using disposable 16-gauge needles. All ears were examined after injection and a x-ray of the ear was taken for record purposes.
- 1 Week Post-procedure
- There were no evidence of swelling, inflammation or edema associated with the injection site or the injections.
- 2 Weeks Post-procedure
- Minor reddish and swelling around each injected bulk was observed.
- 3 Weeks Post-procedure
- All injection sites were easily visible with little evidence of redness or swelling.
- 5 Weeks Post-procedure
- At 5 weeks post-procedure, rabbits #1 and #2 were necropsied.
- The ears as well as the internal organs were examined grossly. Upon dissection of the periauricular tissue on the skull and anterior and posterior to the base of the ear, no beads were observed in the tissues.
- The ears were examined for migration of beads from the site of injection. The examinations were accomplished by tran-illuminating the tissues with bright light. No particles were observed beyond the boundaries of the lesions.
- Stomach/Esophagus
- Procedure
- Using the gastric model, multiple sub-serosal injections were made along the greater curvature of the stomach. Approximately 0.25 ml of material was injected at each of 4 sites in one rabbit and 3 sites in another rabbit. The injections were made using a 1-ml syringe of material and a 16-gauge needle.
- 2 Weeks Post-Procedure
- Observations were consistent with that of the ear data.
- 8 Week Post-Procedure
- At 8 weeks post-procedure, following radiography, both rabbits were necropsied. The following summarizes the results:
- There was no apparent loss of beads or migration of beads from the injection site.
- No gross migration of particles on the surface of the stomach or on the surface of the abdominal structures was noted.
- The injection sites appeared well healed with no evidence of erythema or swelling noted in or about the injection sites.
- Gross examination of the abdominal structures did not demonstrate any gross abnormalities.
- Summary Of Study
- Radiopaque carbon coated beads were injected subcutaneously between the skin and the auricular cartilage on the convex surface of ears, and subs-serosally along the greater curvature of the stomach in rabbits. Weekly examination demonstrated minimal inflammatory response to the injected area. At 5 weeks (ear) and 8 weeks (stomach/esophagus) post-procedure the radiopaque beads appeared stable in place.
Claims (32)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/056,882 US20020082517A1 (en) | 2000-08-15 | 2002-01-25 | Tissue marking using biocompatible microparticles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/638,964 US6394965B1 (en) | 2000-08-15 | 2000-08-15 | Tissue marking using biocompatible microparticles |
US10/056,882 US20020082517A1 (en) | 2000-08-15 | 2002-01-25 | Tissue marking using biocompatible microparticles |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/638,964 Continuation US6394965B1 (en) | 2000-08-15 | 2000-08-15 | Tissue marking using biocompatible microparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020082517A1 true US20020082517A1 (en) | 2002-06-27 |
Family
ID=24562182
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/638,964 Expired - Lifetime US6394965B1 (en) | 2000-08-15 | 2000-08-15 | Tissue marking using biocompatible microparticles |
US10/056,882 Abandoned US20020082517A1 (en) | 2000-08-15 | 2002-01-25 | Tissue marking using biocompatible microparticles |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/638,964 Expired - Lifetime US6394965B1 (en) | 2000-08-15 | 2000-08-15 | Tissue marking using biocompatible microparticles |
Country Status (4)
Country | Link |
---|---|
US (2) | US6394965B1 (en) |
EP (1) | EP1309356A2 (en) |
JP (1) | JP2004506027A (en) |
WO (1) | WO2002013876A2 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050019262A1 (en) * | 2003-07-25 | 2005-01-27 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US20050033157A1 (en) * | 2003-07-25 | 2005-02-10 | Klein Dean A. | Multi-modality marking material and method |
US20050189192A1 (en) * | 2002-09-12 | 2005-09-01 | Luk Lamellen Und Kupplungsbau Beteiligungs Kg | Method for reducing juddering vibrations |
US20050228311A1 (en) * | 2004-03-31 | 2005-10-13 | Beckman Andrew T | Marker device and method of deploying a cavity marker using a surgical biopsy device |
US20060079805A1 (en) * | 2004-10-13 | 2006-04-13 | Miller Michael E | Site marker visable under multiple modalities |
US20060094945A1 (en) * | 2004-10-28 | 2006-05-04 | Sontra Medical Corporation | System and method for analyte sampling and analysis |
US20060159620A1 (en) * | 2002-09-13 | 2006-07-20 | Fernando Donate | Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent |
US20070093726A1 (en) * | 2004-10-13 | 2007-04-26 | Leopold Phillip M | Site marker visible under multiple modalities |
US20070135711A1 (en) * | 2003-07-25 | 2007-06-14 | Rubicor Medical, Inc. | Methods and systems for marking post biopsy cavity sites |
US20070299339A1 (en) * | 2003-07-25 | 2007-12-27 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US20080269603A1 (en) * | 2004-10-13 | 2008-10-30 | Nicoson Zachary R | Site marker visible under multiple modalities |
US20110028831A1 (en) * | 2009-07-30 | 2011-02-03 | Kent James P | Permanently visible implantable fiduciary tissue marker |
US8280486B2 (en) | 2004-10-13 | 2012-10-02 | Suros Surgical Systems, Inc. | Site marker visable under multiple modalities |
US20120253189A1 (en) * | 1999-02-02 | 2012-10-04 | Senoxrx, Inc. | Cavity-filling biopsy site markers |
US8626269B2 (en) | 2003-05-23 | 2014-01-07 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US8634899B2 (en) | 2003-11-17 | 2014-01-21 | Bard Peripheral Vascular, Inc. | Multi mode imaging marker |
US8639315B2 (en) | 2003-05-23 | 2014-01-28 | Senorx, Inc. | Marker or filler forming fluid |
US8668737B2 (en) | 1997-10-10 | 2014-03-11 | Senorx, Inc. | Tissue marking implant |
US8718745B2 (en) | 2000-11-20 | 2014-05-06 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US8784433B2 (en) | 2002-06-17 | 2014-07-22 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
USD715442S1 (en) | 2013-09-24 | 2014-10-14 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715942S1 (en) | 2013-09-24 | 2014-10-21 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716450S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716451S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
US9042965B2 (en) | 2006-12-18 | 2015-05-26 | C. R. Bard, Inc. | Biopsy marker with in situ-generated imaging properties |
US9044162B2 (en) | 1999-02-02 | 2015-06-02 | Senorx, Inc. | Marker delivery device with releasable plug |
US9149341B2 (en) | 1999-02-02 | 2015-10-06 | Senorx, Inc | Deployment of polysaccharide markers for treating a site within a patient |
US9579077B2 (en) | 2006-12-12 | 2017-02-28 | C.R. Bard, Inc. | Multiple imaging mode tissue marker |
US9820824B2 (en) | 1999-02-02 | 2017-11-21 | Senorx, Inc. | Deployment of polysaccharide markers for treating a site within a patent |
US9848956B2 (en) | 2002-11-18 | 2017-12-26 | Bard Peripheral Vascular, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
US10172674B2 (en) | 1999-02-02 | 2019-01-08 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US10258428B2 (en) | 2008-12-30 | 2019-04-16 | C. R. Bard, Inc. | Marker delivery device for tissue marker placement |
US10342635B2 (en) | 2005-04-20 | 2019-07-09 | Bard Peripheral Vascular, Inc. | Marking device with retractable cannula |
US10786604B2 (en) | 2008-09-23 | 2020-09-29 | Senorx, Inc. | Porous bioabsorbable implant |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7637948B2 (en) | 1997-10-10 | 2009-12-29 | Senorx, Inc. | Tissue marking implant |
US6161034A (en) * | 1999-02-02 | 2000-12-12 | Senorx, Inc. | Methods and chemical preparations for time-limited marking of biopsy sites |
US6725083B1 (en) | 1999-02-02 | 2004-04-20 | Senorx, Inc. | Tissue site markers for in VIVO imaging |
US20080039819A1 (en) * | 2006-08-04 | 2008-02-14 | Senorx, Inc. | Marker formed of starch or other suitable polysaccharide |
US6575991B1 (en) | 1999-06-17 | 2003-06-10 | Inrad, Inc. | Apparatus for the percutaneous marking of a lesion |
US6394965B1 (en) * | 2000-08-15 | 2002-05-28 | Carbon Medical Technologies, Inc. | Tissue marking using biocompatible microparticles |
EP1402243B1 (en) * | 2001-05-17 | 2006-08-16 | Xenogen Corporation | Method and apparatus for determining target depth, brightness and size within a body region |
US7298415B2 (en) | 2001-07-13 | 2007-11-20 | Xenogen Corporation | Structured light imaging apparatus |
JP2005524659A (en) * | 2002-02-27 | 2005-08-18 | カーボン・メディカル・テクノロジーズ・インコーポレーテッド | Lower esophageal tissue regulator |
US20030161824A1 (en) | 2002-02-27 | 2003-08-28 | Rackley Raymond R. | Bulking agent needle apparatus and method of using the needle apparatus |
US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
US7053134B2 (en) * | 2002-04-04 | 2006-05-30 | Scimed Life Systems, Inc. | Forming a chemically cross-linked particle of a desired shape and diameter |
US20040105890A1 (en) * | 2002-05-28 | 2004-06-03 | Carbon Medical Technologies, Inc. | Biocompatible injectable materials |
CA2492339A1 (en) | 2002-06-12 | 2003-12-24 | Boston Scientific Limited | Bulking agents |
US7599731B2 (en) * | 2002-07-16 | 2009-10-06 | Xenogen Corporation | Fluorescent light tomography |
US7616985B2 (en) * | 2002-07-16 | 2009-11-10 | Xenogen Corporation | Method and apparatus for 3-D imaging of internal light sources |
US7842377B2 (en) * | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
US20050119562A1 (en) * | 2003-05-23 | 2005-06-02 | Senorx, Inc. | Fibrous marker formed of synthetic polymer strands |
US7001341B2 (en) * | 2003-08-13 | 2006-02-21 | Scimed Life Systems, Inc. | Marking biopsy sites |
US7976823B2 (en) | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
US20050234336A1 (en) * | 2004-03-26 | 2005-10-20 | Beckman Andrew T | Apparatus and method for marking tissue |
US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
US8425550B2 (en) | 2004-12-01 | 2013-04-23 | Boston Scientific Scimed, Inc. | Embolic coils |
US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
US7727555B2 (en) | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
US8044996B2 (en) * | 2005-05-11 | 2011-10-25 | Xenogen Corporation | Surface construction using combined photographic and structured light information |
US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
US8052658B2 (en) | 2005-10-07 | 2011-11-08 | Bard Peripheral Vascular, Inc. | Drug-eluting tissue marker |
US8007509B2 (en) | 2005-10-12 | 2011-08-30 | Boston Scientific Scimed, Inc. | Coil assemblies, components and methods |
US11241296B2 (en) | 2005-11-17 | 2022-02-08 | Breast-Med, Inc. | Imaging fiducial markers and methods |
US7702378B2 (en) * | 2005-11-17 | 2010-04-20 | Breast-Med, Inc. | Tissue marker for multimodality radiographic imaging |
US20070135706A1 (en) * | 2005-12-13 | 2007-06-14 | Shimko Daniel A | Debridement method, device and kit |
US8152839B2 (en) | 2005-12-19 | 2012-04-10 | Boston Scientific Scimed, Inc. | Embolic coils |
US8101197B2 (en) | 2005-12-19 | 2012-01-24 | Stryker Corporation | Forming coils |
US7947368B2 (en) | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
US8673398B2 (en) * | 2006-02-23 | 2014-03-18 | Meadwestvaco Corporation | Method for treating a substrate |
US7569053B2 (en) * | 2006-03-03 | 2009-08-04 | Intact Medical Corporation | Apparatus for retrieving a tissue volume with improved positioning precursor assembly |
US7771339B2 (en) * | 2006-05-31 | 2010-08-10 | Ab Mimator | Method and system for radiotherapy treatment |
US10775308B2 (en) * | 2006-08-24 | 2020-09-15 | Xenogen Corporation | Apparatus and methods for determining optical tissue properties |
US10335038B2 (en) | 2006-08-24 | 2019-07-02 | Xenogen Corporation | Spectral unmixing for in-vivo imaging |
EP2079385B1 (en) | 2006-10-23 | 2013-11-20 | C.R.Bard, Inc. | Breast marker |
US8414927B2 (en) | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Cross-linked polymer particles |
US20080287729A1 (en) * | 2007-05-16 | 2008-11-20 | Anthony Biscotti | Interstitial marker and method for creation thereof |
US9238046B2 (en) * | 2007-09-21 | 2016-01-19 | The Trustees Of The University Of Pennsylvania | Prevention of infarct expansion |
US8311610B2 (en) | 2008-01-31 | 2012-11-13 | C. R. Bard, Inc. | Biopsy tissue marker |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US10634741B2 (en) | 2009-12-04 | 2020-04-28 | Endomagnetics Ltd. | Magnetic probe apparatus |
US9427186B2 (en) * | 2009-12-04 | 2016-08-30 | Endomagnetics Ltd. | Magnetic probe apparatus |
CN104736184A (en) * | 2012-06-04 | 2015-06-24 | 米格拉塔英国有限公司 | Medical use of particles of titanium and/or titanium oxide |
CN105283202B (en) | 2013-03-11 | 2019-04-23 | 安都磁学有限公司 | Hypotonic solution for lymph node detection |
US9239314B2 (en) | 2013-03-13 | 2016-01-19 | Endomagnetics Ltd. | Magnetic detector |
US9234877B2 (en) | 2013-03-13 | 2016-01-12 | Endomagnetics Ltd. | Magnetic detector |
US9795455B2 (en) | 2014-08-22 | 2017-10-24 | Breast-Med, Inc. | Tissue marker for multimodality radiographic imaging |
KR20160081840A (en) * | 2014-12-30 | 2016-07-08 | (주) 더스탠다드 | Endoscopy marker for tissue strain |
EP4085866A3 (en) | 2015-06-04 | 2023-01-18 | Endomagnetics Ltd. | Marker materials and forms for magnetic marker localization |
US11701451B1 (en) | 2022-03-11 | 2023-07-18 | Carbon Medical Technologies, Inc. | Soft tissue filler and methods |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5935084A (en) * | 1997-09-30 | 1999-08-10 | Johnson & Johnson Professional, Inc. | Inflatable pressure indicator |
US5976500A (en) * | 1990-04-10 | 1999-11-02 | Imarx Pharmaceutical Corp. | Gel particle contrast media for magnetic resonance imaging |
US6174330B1 (en) * | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US6228055B1 (en) * | 1994-09-16 | 2001-05-08 | Ethicon Endo-Surgery, Inc. | Devices for marking and defining particular locations in body tissue |
US6394965B1 (en) * | 2000-08-15 | 2002-05-28 | Carbon Medical Technologies, Inc. | Tissue marking using biocompatible microparticles |
US20030036697A1 (en) * | 1999-08-13 | 2003-02-20 | Ottoboni Thomas B. | Hollow microspheres with controlled fragility for medical use |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3334050A (en) | 1964-08-24 | 1967-08-01 | Minnesota Mining & Mfg | Organic carbonaceous matrix with radioisotope dispersed therein |
US3746650A (en) | 1970-02-26 | 1973-07-17 | Minnesota Mining & Mfg | Organic radioisotope-containing carbonaceous matrix heated in inert atmosphere |
US4341220A (en) | 1979-04-13 | 1982-07-27 | Pfizer Inc. | Stereotactic surgery apparatus and method |
CA1225585A (en) | 1983-06-30 | 1987-08-18 | Maria T. Litvinova | Composition for embolization of blood vessels |
US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US4795463A (en) | 1984-10-03 | 1989-01-03 | Baylor College Of Medicine | Labeled breast prosthesis and methods for detecting and predicting rupture of the prosthesis |
US4627853A (en) | 1985-05-29 | 1986-12-09 | American Hospital Supply Corporation | Method of producing prostheses for replacement of articular cartilage and prostheses so produced |
US4709703A (en) | 1985-11-12 | 1987-12-01 | Mayo Foundation | Imaging system and method using radiopaque microspheres for evaluation of organ tissue perfusion |
DE3831657A1 (en) | 1988-09-17 | 1990-03-22 | Boehringer Ingelheim Kg | DEVICE FOR THE OSTEOSYNTHESIS AND METHOD FOR THE PRODUCTION THEREOF |
US5236410A (en) | 1990-08-02 | 1993-08-17 | Ferrotherm International, Inc. | Tumor treatment method |
EP0470569B1 (en) | 1990-08-08 | 1995-11-22 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis inhibiting substance |
FR2676927B1 (en) | 1991-05-29 | 1995-06-23 | Ibf | MICROSPHERES FOR USE IN THERAPEUTIC VASCULAR OCCLUSIONS AND INJECTABLE SOLUTIONS CONTAINING THEM. |
JP3356447B2 (en) | 1991-10-16 | 2002-12-16 | テルモ株式会社 | Vascular lesion embolic material composed of dried polymer gel |
US5282827A (en) | 1991-11-08 | 1994-02-01 | Kensey Nash Corporation | Hemostatic puncture closure system and method of use |
USRE36461E (en) | 1991-12-13 | 1999-12-21 | Beekley Corporation | Radiology marker system and dispenser |
US5366507A (en) | 1992-03-06 | 1994-11-22 | Sottosanti John S | Method for use in bone tissue regeneration |
US5382260A (en) | 1992-10-30 | 1995-01-17 | Interventional Therapeutics Corp. | Embolization device and apparatus including an introducer cartridge and method for delivering the same |
DE4306277C2 (en) | 1993-03-01 | 2000-11-02 | Leibinger Gmbh | Operation marking tool |
WO1994021196A2 (en) | 1993-03-18 | 1994-09-29 | C.R. Bard, Inc. | Endovascular stents |
US5451406A (en) | 1994-07-14 | 1995-09-19 | Advanced Uroscience, Inc. | Tissue injectable composition and method of use |
US5888546A (en) | 1995-08-28 | 1999-03-30 | The Regents Of The University Of California | Embolic material for endovascular occlusion of abnormal vasculature and method for using the same |
US5702361A (en) | 1996-01-31 | 1997-12-30 | Micro Therapeutics, Inc. | Method for embolizing blood vessels |
US5792478A (en) | 1996-07-08 | 1998-08-11 | Advanced Uro Science | Tissue injectable composition and method of use |
US5902310A (en) | 1996-08-12 | 1999-05-11 | Ethicon Endo-Surgery, Inc. | Apparatus and method for marking tissue |
JP3784112B2 (en) | 1996-08-15 | 2006-06-07 | 株式会社カネカメディックス | Coiled embolic material |
US5676146B1 (en) | 1996-09-13 | 2000-04-18 | Osteotech Inc | Surgical implant containing a resorbable radiopaque marker and method of locating such within a body |
US5830230A (en) | 1997-03-07 | 1998-11-03 | Micro Therapeutics, Inc. | Method of intracranial vascular embolotherapy using self anchoring coils |
WO1999012577A1 (en) | 1997-09-05 | 1999-03-18 | Nycomed Imaging As | Polymer particles made of polyvinyl alcohol and comprising a contrast agent for chemoembolization |
CA2318546A1 (en) | 1998-02-27 | 1999-09-02 | Micro Therapeutics, Inc. | Gynecologic endovascular embolotherapy methods |
US6059766A (en) | 1998-02-27 | 2000-05-09 | Micro Therapeutics, Inc. | Gynecologic embolotherapy methods |
WO1999044643A1 (en) | 1998-03-06 | 1999-09-10 | Biosepra Medical Inc. | Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles |
US6161034A (en) | 1999-02-02 | 2000-12-12 | Senorx, Inc. | Methods and chemical preparations for time-limited marking of biopsy sites |
US6347241B2 (en) | 1999-02-02 | 2002-02-12 | Senorx, Inc. | Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it |
US6015424A (en) | 1998-04-28 | 2000-01-18 | Microvention, Inc. | Apparatus and method for vascular embolization |
US5941890A (en) | 1998-06-26 | 1999-08-24 | Ethicon Endo-Surgery, Inc. | Implantable surgical marker |
US6056700A (en) | 1998-10-13 | 2000-05-02 | Emx, Inc. | Biopsy marker assembly and method of use |
US6371904B1 (en) | 1998-12-24 | 2002-04-16 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US6086544A (en) | 1999-03-31 | 2000-07-11 | Ethicon Endo-Surgery, Inc. | Control apparatus for an automated surgical biopsy device |
US6083202A (en) * | 1999-10-14 | 2000-07-04 | Syntheon, Llc | Endoscopic needle injection device |
US6355275B1 (en) * | 2000-06-23 | 2002-03-12 | Carbon Medical Technologies, Inc. | Embolization using carbon coated microparticles |
-
2000
- 2000-08-15 US US09/638,964 patent/US6394965B1/en not_active Expired - Lifetime
-
2001
- 2001-08-13 EP EP01962146A patent/EP1309356A2/en not_active Withdrawn
- 2001-08-13 JP JP2002519014A patent/JP2004506027A/en active Pending
- 2001-08-13 WO PCT/US2001/025352 patent/WO2002013876A2/en not_active Application Discontinuation
-
2002
- 2002-01-25 US US10/056,882 patent/US20020082517A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5976500A (en) * | 1990-04-10 | 1999-11-02 | Imarx Pharmaceutical Corp. | Gel particle contrast media for magnetic resonance imaging |
US6228055B1 (en) * | 1994-09-16 | 2001-05-08 | Ethicon Endo-Surgery, Inc. | Devices for marking and defining particular locations in body tissue |
US6174330B1 (en) * | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US5935084A (en) * | 1997-09-30 | 1999-08-10 | Johnson & Johnson Professional, Inc. | Inflatable pressure indicator |
US20030036697A1 (en) * | 1999-08-13 | 2003-02-20 | Ottoboni Thomas B. | Hollow microspheres with controlled fragility for medical use |
US6394965B1 (en) * | 2000-08-15 | 2002-05-28 | Carbon Medical Technologies, Inc. | Tissue marking using biocompatible microparticles |
Cited By (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9039763B2 (en) | 1997-10-10 | 2015-05-26 | Senorx, Inc. | Tissue marking implant |
US8668737B2 (en) | 1997-10-10 | 2014-03-11 | Senorx, Inc. | Tissue marking implant |
US8965486B2 (en) | 1999-02-02 | 2015-02-24 | Senorx, Inc. | Cavity filling biopsy site markers |
US9149341B2 (en) | 1999-02-02 | 2015-10-06 | Senorx, Inc | Deployment of polysaccharide markers for treating a site within a patient |
US9820824B2 (en) | 1999-02-02 | 2017-11-21 | Senorx, Inc. | Deployment of polysaccharide markers for treating a site within a patent |
US9649093B2 (en) | 1999-02-02 | 2017-05-16 | Senorx, Inc. | Cavity-filling biopsy site markers |
US9237937B2 (en) | 1999-02-02 | 2016-01-19 | Senorx, Inc. | Cavity-filling biopsy site markers |
US8626270B2 (en) * | 1999-02-02 | 2014-01-07 | Senorx, Inc. | Cavity-filling biopsy site markers |
US10172674B2 (en) | 1999-02-02 | 2019-01-08 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US9861294B2 (en) | 1999-02-02 | 2018-01-09 | Senorx, Inc. | Marker delivery device with releasable plug |
US9044162B2 (en) | 1999-02-02 | 2015-06-02 | Senorx, Inc. | Marker delivery device with releasable plug |
US20120253189A1 (en) * | 1999-02-02 | 2012-10-04 | Senoxrx, Inc. | Cavity-filling biopsy site markers |
US8718745B2 (en) | 2000-11-20 | 2014-05-06 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US8784433B2 (en) | 2002-06-17 | 2014-07-22 | Senorx, Inc. | Plugged tip delivery tube for marker placement |
US20050189192A1 (en) * | 2002-09-12 | 2005-09-01 | Luk Lamellen Und Kupplungsbau Beteiligungs Kg | Method for reducing juddering vibrations |
US7119069B2 (en) | 2002-09-13 | 2006-10-10 | Attenuon, Llc | Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent |
US20060159620A1 (en) * | 2002-09-13 | 2006-07-20 | Fernando Donate | Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent |
US9848956B2 (en) | 2002-11-18 | 2017-12-26 | Bard Peripheral Vascular, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
US10813716B2 (en) | 2002-11-18 | 2020-10-27 | Bard Peripheral Vascular, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
US8626269B2 (en) | 2003-05-23 | 2014-01-07 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US10299881B2 (en) | 2003-05-23 | 2019-05-28 | Senorx, Inc. | Marker or filler forming fluid |
US10045832B2 (en) | 2003-05-23 | 2018-08-14 | Senorx, Inc. | Marker or filler forming fluid |
US9801688B2 (en) | 2003-05-23 | 2017-10-31 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US8880154B2 (en) | 2003-05-23 | 2014-11-04 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US8639315B2 (en) | 2003-05-23 | 2014-01-28 | Senorx, Inc. | Marker or filler forming fluid |
US20070299541A1 (en) * | 2003-07-25 | 2007-12-27 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US8092779B2 (en) | 2003-07-25 | 2012-01-10 | Rubicor Medical, Llc | Post-biopsy cavity treatment implants and methods |
US7744852B2 (en) | 2003-07-25 | 2010-06-29 | Rubicor Medical, Llc | Methods and systems for marking post biopsy cavity sites |
US7780948B2 (en) | 2003-07-25 | 2010-08-24 | Rubicor Medical, Llc | Post biopsy cavity treatment implants and methods |
US8491630B2 (en) | 2003-07-25 | 2013-07-23 | Encapsule Medical, LLC. | Post-biopsy cavity treatment implants and methods |
US20050033157A1 (en) * | 2003-07-25 | 2005-02-10 | Klein Dean A. | Multi-modality marking material and method |
US20050019262A1 (en) * | 2003-07-25 | 2005-01-27 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US20070135711A1 (en) * | 2003-07-25 | 2007-06-14 | Rubicor Medical, Inc. | Methods and systems for marking post biopsy cavity sites |
US20070299339A1 (en) * | 2003-07-25 | 2007-12-27 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US7537788B2 (en) | 2003-07-25 | 2009-05-26 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US20080114329A1 (en) * | 2003-10-16 | 2008-05-15 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US7534452B2 (en) | 2003-10-16 | 2009-05-19 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US8634899B2 (en) | 2003-11-17 | 2014-01-21 | Bard Peripheral Vascular, Inc. | Multi mode imaging marker |
US20090088665A1 (en) * | 2004-03-31 | 2009-04-02 | Beckman Andrew T | Marker device and method of deploying a cavity marker using a surgical biopsy device |
US20050228311A1 (en) * | 2004-03-31 | 2005-10-13 | Beckman Andrew T | Marker device and method of deploying a cavity marker using a surgical biopsy device |
US7465279B2 (en) | 2004-03-31 | 2008-12-16 | Ethicon Endo-Surgery, Inc. | Marker device and method of deploying a cavity marker using a surgical biopsy device |
US8060183B2 (en) | 2004-10-13 | 2011-11-15 | Suros Surgical Systems, Inc. | Site marker visible under multiple modalities |
US8352014B2 (en) | 2004-10-13 | 2013-01-08 | Suros Surgical Systems, Inc. | Site marker visible under multiple modalities |
US8442623B2 (en) | 2004-10-13 | 2013-05-14 | Suros Surgical Systems, Inc. | Site marker visible under multiple modalities |
US20080269603A1 (en) * | 2004-10-13 | 2008-10-30 | Nicoson Zachary R | Site marker visible under multiple modalities |
US8280486B2 (en) | 2004-10-13 | 2012-10-02 | Suros Surgical Systems, Inc. | Site marker visable under multiple modalities |
US20070093726A1 (en) * | 2004-10-13 | 2007-04-26 | Leopold Phillip M | Site marker visible under multiple modalities |
US20060079805A1 (en) * | 2004-10-13 | 2006-04-13 | Miller Michael E | Site marker visable under multiple modalities |
US8224414B2 (en) * | 2004-10-28 | 2012-07-17 | Echo Therapeutics, Inc. | System and method for analyte sampling and analysis with hydrogel |
US20060094946A1 (en) * | 2004-10-28 | 2006-05-04 | Sontra Medical Corporation | System and method for analyte sampling and analysis with hydrogel |
US20060094945A1 (en) * | 2004-10-28 | 2006-05-04 | Sontra Medical Corporation | System and method for analyte sampling and analysis |
US11278370B2 (en) | 2005-04-20 | 2022-03-22 | Bard Peripheral Vascular, Inc. | Marking device with retractable cannula |
US10342635B2 (en) | 2005-04-20 | 2019-07-09 | Bard Peripheral Vascular, Inc. | Marking device with retractable cannula |
US10357328B2 (en) | 2005-04-20 | 2019-07-23 | Bard Peripheral Vascular, Inc. and Bard Shannon Limited | Marking device with retractable cannula |
US10682200B2 (en) | 2006-12-12 | 2020-06-16 | C. R. Bard, Inc. | Multiple imaging mode tissue marker |
US9579077B2 (en) | 2006-12-12 | 2017-02-28 | C.R. Bard, Inc. | Multiple imaging mode tissue marker |
US9901415B2 (en) | 2006-12-12 | 2018-02-27 | C. R. Bard, Inc. | Multiple imaging mode tissue marker |
US11471244B2 (en) | 2006-12-12 | 2022-10-18 | C.R. Bard, Inc. | Multiple imaging mode tissue marker |
US9042965B2 (en) | 2006-12-18 | 2015-05-26 | C. R. Bard, Inc. | Biopsy marker with in situ-generated imaging properties |
US11833275B2 (en) | 2008-09-23 | 2023-12-05 | Senorx, Inc. | Porous bioabsorbable implant |
US10786604B2 (en) | 2008-09-23 | 2020-09-29 | Senorx, Inc. | Porous bioabsorbable implant |
US10258428B2 (en) | 2008-12-30 | 2019-04-16 | C. R. Bard, Inc. | Marker delivery device for tissue marker placement |
US11779431B2 (en) | 2008-12-30 | 2023-10-10 | C. R. Bard, Inc. | Marker delivery device for tissue marker placement |
US20110028831A1 (en) * | 2009-07-30 | 2011-02-03 | Kent James P | Permanently visible implantable fiduciary tissue marker |
USD715942S1 (en) | 2013-09-24 | 2014-10-21 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715442S1 (en) | 2013-09-24 | 2014-10-14 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716450S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716451S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
Also Published As
Publication number | Publication date |
---|---|
WO2002013876A2 (en) | 2002-02-21 |
EP1309356A2 (en) | 2003-05-14 |
WO2002013876A3 (en) | 2003-01-23 |
US6394965B1 (en) | 2002-05-28 |
JP2004506027A (en) | 2004-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6394965B1 (en) | Tissue marking using biocompatible microparticles | |
US6355275B1 (en) | Embolization using carbon coated microparticles | |
US7877133B2 (en) | Marker or filler forming fluid | |
AU774994B2 (en) | Device and method for safe location and marking of a cavity and sentinel lymph nodes | |
US20210121263A1 (en) | Tissue markers | |
US20130066195A1 (en) | Device and method for safe location and marking of a cavity and sentinel lymph nodes | |
JP2003517453A (en) | Methods and chemical formulations for time-limited marking of biological sites | |
Fajardo et al. | Placement of endovascular embolization microcoils to localize the site of breast lesions removed at stereotactic core biopsy. | |
JP2021510574A (en) | Systems and methods for closing pathways within an organization | |
Mullen et al. | The use of carbon marking after stereotactic large-core-needle breast biopsy | |
US9669113B1 (en) | Device and method for safe location and marking of a biopsy cavity | |
WO2023031387A1 (en) | Use of nanoparticles for the treatment of fistulizing anoperineal lesions | |
JP2014528000A (en) | Composition for radiofrequency ablation therapy | |
Farouk et al. | Charcoal localization for surgical resection of non-palpable suspicious breast lesions | |
EP1666077A2 (en) | Surgical carrier material with silver particles, medical product containing the carrier material and method for detection of the carrier material as well as of adhesions | |
Zada et al. | Injectable Biodegradable Multimodal Mammography Marker | |
Schulz-Wendtland et al. | Breast imaging and interventional procedures–the basis for oncoplastic breast surgery | |
Li et al. | Development of an MRI/x-ray/ultrasound compatible marker for pre-operative breast tumour localization | |
KR20240055804A (en) | Use of Nanoparticles for the Treatment of Fistulatic An perineal Lesions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CARBON MEDICAL TECHNOLOGIES, INC., MINNESOTA Free format text: CHANGE OF NAME;ASSIGNOR:ADVANCED UROSCIENCE;REEL/FRAME:012535/0898 Effective date: 20001117 |
|
AS | Assignment |
Owner name: CARBON MEDICAL TECHNOLOGIES, INC., MINNESOTA Free format text: CHANGE OF NAME;ASSIGNOR:ADVANCED UROSCIENCE;REEL/FRAME:012440/0257 Effective date: 20001117 |
|
AS | Assignment |
Owner name: ADVANCED UROSCIENCE, MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KLEIN, DEAN A.;REEL/FRAME:012549/0923 Effective date: 20000815 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |